China SXT Pharmaceuticals (SXTC) Total Debt (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Total Debt of $999565.0 for Q1 2026, up 851.56% year-on-year from $105045.0 in Q1 2025, and up 1188.48% on a QoQ basis from $77577.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Total Debt (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals (SXTC) has reported Total Debt for 9 consecutive years, with $999565.0 the latest figure, recorded in Q1 2026.
- Quarterly Total Debt rose 851.56% year-over-year to $999565.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $999565.0 (up 851.56% YoY) and the FY2026 annual result came in at $999565.0, up 851.56% from the prior year.
- Total Debt advanced to $999565.0 in Q1 2026 per SXTC's latest filing, from $77577.0 in the prior quarter.
- Over the last five years, Total Debt for SXTC reached as high as $1.2 million in Q3 2022 and fell as low as $77577.0 in Q3 2025.
- A 5-year average of $594175.4 and a median of $610183.0 in 2024 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2022 — Total Debt slumped 95.33% — and 2026, when it surged 851.56%.
- Year by year, Total Debt stood at $1.2 million in 2022, then slumped by 90.68% to $112397.0 in 2023, then soared by 627.36% to $817528.0 in 2024, then plunged by 90.51% to $77577.0 in 2025, then surged by 1188.48% to $999565.0 in 2026.
- According to Business Quant data, Total Debt over the past three periods registered $999565.0, $77577.0, and $105045.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 11.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.63 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 28.76 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.34 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.81 Bn |
| 10 | China SXT Pharmaceuticals | 7.11 Mn | -21.06 Mn | - | 999,565.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 999,565.00 |
| Sep 30, 2025 | 77,577.00 |
| Mar 31, 2025 | 105,045.00 |
| Sep 30, 2024 | 817,528.00 |
| Mar 31, 2024 | 610,183.00 |
| Sep 30, 2023 | 112,397.00 |
| Mar 31, 2023 | 285,315.00 |
| Sep 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Sep 30, 2021 | 2.12 Mn |
| Mar 31, 2021 | 24.30 Mn |
| Sep 30, 2020 | 60,970.00 |
| Mar 31, 2020 | 6.68 Mn |
| Sep 30, 2019 | 1.89 Mn |
| Mar 31, 2019 | 2.52 Mn |
| Sep 30, 2018 | 205,452.00 |